UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Summary of changes)

Abstract

The most recent Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration- naive and castration-sensitive prostate cancer (mCNPC/ mCSPC) was published in 2020.1 New data in this patient population have prompted an update to the guideline in order to add treatment options that have proven to improve disease progression and overall survival (OS). This brief review summarizes the changes in the guideline, as well as the importance of ensuring proper treatment intensification in addition to androgen deprivation therapy (ADT) in patients with metastatic hormone-naive or castration-sensitive prostate cancer.